Skip to main content
Premium Trial:

Request an Annual Quote

Bruker's Non-Affiliated Shareholders Approve BioSpin Buy, Name Change

NEW YORK (GenomeWeb News) – Bruker BioSciences today said that its non-affiliated stockholders have approved the acquisition of Bruker BioSpin.
 
Bruker’s $914 million acquisition of sister company BioSpin cleared the US antitrust period last month. BioSpin is 100 percent owned by members of the Laukien family, who also own 52 percent of Bruker BioSciences. Following completion of the deal, the combined firm will be renamed Bruker Corporation and 60 percent of its shares will be held by the Laukien family.
 
In addition to approving the acquisition, shareholders approved amendments to the firm’s certificate of incorporation including the name change.
 
The firm also said today that Tony Keller, executive chairman and former CEO of BioSpin, and Dirk Laukien, president of Bruker Optics, were elected to serve on Bruker’s board of directors.

The Scan

Removal Inquiry

The Wall Street Journal reports that US lawmakers are seeking additional information about the request to remove SARS-CoV-2 sequence data from a database run by the National Institutes of Health.

Likely to End in Spring

Free lateral flow testing for SARS-CoV-2 may end in the UK by next spring, the head of Innova Medical Group says, according to the Financial Times.

Searching for More Codes

NPR reports that the US Department of Justice has accused an insurance and a data mining company of fraud.

Genome Biology Papers on GWAS Fine-Mapping Method, COVID-19 Susceptibility, Rheumatoid Arthritis

In Genome Biology this week: integrative fine-mapping approach, analysis of locus linked to COVID-19 susceptibility and severity, and more.